about
Hypersensitivity Responses in the Central Nervous SystemUpdate on biomarkers in neuromyelitis opticaMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeNeuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO).Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination.Demographic and clinical features of neuromyelitis optica: A review.Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier.Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.Interferon alpha association with neuromyelitis optica.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.Neuromyelitis optica (NMO)--an autoimmune disease of the central nervous system (CNS).Interferons in the central nervous system: a few instruments play many tunes.Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.A population-based prospective study of optic neuritis.Antibodies against interferon-beta in neuromyelitis optica patients.Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations.Magnetic resonance imaging findings at the first episode of acute optic neuritis.Neuromyelitis optica-like pathology is dependent on type I interferon response.Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid.Parental ethnicity associated with risk for multiple sclerosis: A population-based incident case-control study in Iran.Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort.Selective localization of IgG from cerebrospinal fluid to brain parenchyma.Racial differences in neuromyelitis optica spectrum disorderEnvironmental risk factors in neuromyelitis optica spectrum disorder: a case–control studyP wave duration and dispersion and QT interval in multiple sclerosisHLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis opticaCerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort studyVocal cord paralysis as primary and secondary results of malignancy. A prospective descriptive studyOptical coherence tomography in acute optic neuritis: A population-based studyPregnancy outcomes in a woman with neuromyelitis opticaA comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatmentReader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in DenmarkLong-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective studyPrimary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management
P50
Q26779177-9ABFB84A-62E9-4418-9560-98AB3F7EA551Q26799789-1AADF4D1-6D1E-446D-9D74-0BB59CCD00B3Q30371412-7DB8611C-3269-492A-8ABD-4094BDFCD9ADQ30649660-DEE4B3C7-FA7E-44C0-A4E2-EB26A26A135EQ30670938-8B081379-2C54-4FE4-BBF0-ED899F6F9736Q33592132-B579DA4A-1019-4ABA-A7FC-A66DB5AD7238Q33831179-2C2514FF-22F4-46F8-AC4E-67B931857260Q35718428-514F3910-68C3-4739-8C80-ADF918945ADBQ36010441-B8FA3A51-6DFC-469E-8CFB-83A2E91CEC5FQ36753462-B23D9CA2-4A92-4839-BA4F-A3D18E639E29Q37015396-8DE0FFBF-E627-480F-9E6F-38C673F7B2F3Q37374434-D29A5D4B-78D1-4AC7-A510-DAA28C5FF3BDQ37375268-594969AD-8676-4904-B0C3-4537AF85F14FQ37383474-15F38293-8A76-4D4E-91CA-1EEB742441E4Q37383555-1D8491CF-F40E-4057-818C-E9BC6BCAA8F6Q37794273-28AC1EEE-FE0D-4755-AAF9-BBAF6568E163Q38192651-82D754DD-728A-433F-AC51-B1A673CE3005Q40281523-36E6284A-B3DE-434B-A5D4-279244417110Q42694999-D7471521-9838-4297-9376-57B3C3BD203AQ45976760-47499F87-FB2B-40AE-9EE5-CCA164E43922Q47590986-4F231209-C256-49AD-BDE6-8001BFED4588Q47888136-876E7E44-9A58-45C7-A571-12A25A69F459Q48151829-FE974716-8792-448F-9DED-66D1324F4E97Q48198452-A68DB040-70D8-4CA4-B6F2-D8ED88451D55Q48352363-0CB694A0-F808-477E-8277-8D13289FDCB7Q49895708-E3E8B856-832D-4137-95E1-0BCCBA4A0AC2Q53837202-D7C6BBFF-DBC5-422A-8F8C-B02A4F5DA0D3Q55332083-D9EB2D62-C76F-41EF-B4B6-99C3E5AECF01Q58115694-7FFF4F43-2217-4DC8-BEA6-1B18F0E47F2BQ58435991-5BC7566D-101A-493E-BC0B-7F18F1E02F1EQ61473493-728D8C2E-18FD-4FC1-8EAC-AA10FBE16529Q61566396-D9815EFC-347D-4B93-9EDE-03484CD97C9AQ64108144-6F63AC21-6830-483D-8F68-A023464CB519Q64110201-9485957E-E79E-4C30-BD9E-788672223FBAQ64122844-A3CEEFC4-E1D7-45C8-8B3D-387C1789E21FQ85345644-6605CF64-F6C2-4C4D-B13B-F1973331166DQ87873101-F786CA71-27F7-47B8-907E-5E6A70955EAAQ90701588-861F7179-1BE7-474B-AF4D-1A18CB0D9772Q91011686-DB3F7CA4-A5D8-487B-B49F-EB79C20B745FQ91665236-EF5A861F-6E1A-4E1F-BABC-DAB9C53A2809
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8551-0947
@en
name
Nasrin Asgari
@ast
Nasrin Asgari
@en
Nasrin Asgari
@es
Nasrin Asgari
@nl
type
label
Nasrin Asgari
@ast
Nasrin Asgari
@en
Nasrin Asgari
@es
Nasrin Asgari
@nl
prefLabel
Nasrin Asgari
@ast
Nasrin Asgari
@en
Nasrin Asgari
@es
Nasrin Asgari
@nl
P106
P31
P496
0000-0001-8551-0947